Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07540897 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
A Phase 3 study, sponsored by Alkermes.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT07540897 is a Phase 3 study that is actively recruiting participants, run by Alkermes. The registered enrollment target is 150 participants.
The verdict
NCT07540897, a Phase 3 study, is actively recruiting participants, sponsored by Alkermes.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.
Interventions
- DRUG Placebo
- DRUG ALKS 2680 Dose 1
- DRUG ALKS 2680 Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07540897
The ClinicalTrials.gov registry entry for NCT07540897 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07540897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07540897 about?
NCT07540897 is a clinical study titled "A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)". The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.
What is the current status of trial NCT07540897?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-06. Estimated completion is 2027-07.
What interventions are being tested in trial NCT07540897?
The interventions under investigation include: Placebo (DRUG), ALKS 2680 Dose 1 (DRUG), ALKS 2680 Dose 2 (DRUG).
Who is sponsoring clinical trial NCT07540897?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.